Amarex played Nader and company. Partial information with hints of more to come... but they held it back... hence the three fingers in anticipation of the remainder. Sly move, worthy of a lawsuit. Oh, yes, speaking of that, how much better we are in our bargaining position overall as they must do everything possible to keep what happened out of the public eye. Samsung could own Amarex. Waiting on a Show Cause for them to join in with Sidley. Fraud can do you in just when you think you have escaped. What headlines that suit would make. Could be some of the best PR to date for leronlimab. Don't you know the BOD and Advisory members are doing some hefty wrangling back and forth. I think they have got it about figured out. The new CEO will tell the tale whether he speaks about it or not. I bet not. These things have to be done on the quiet side.
Kind of like Dr. Laz saying around minute 22 of that presentation to NIH.... oh how he regrets for not speaking out strongly about the FDA reducing from 4 to 2 doses. So that's all in the past and the future dealings will be done with eyes wide open and retort anticipated and prepared. $CYDY$ long and getting longer.
The time to report the review of data was anticipated June 15 or sooner. Time is ticking. Anticipated Study Completion Date :
Jun 15, 2022 y to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
Sponsor
CytoDyn, Inc. (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT04347239
Collaborator
(none)
394
Enrollment
18
Locations
2
Arms
26
Anticipated Duration (Months)
21.9
Patients Per Site
0.8
Patients Per Site Per Month
Study Details
Study Description
Brief Summary
The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
Condition or Disease Intervention/Treatment Phase
Coronavirus Disease 2019
News 
Market Data 
Discover 
